AML Clinical Trial Tracker — Monitor Acute Myeloid Leukemia Research in 2026

Why AML trial monitoring is uniquely challenging

Acute myeloid leukemia has one of the most rapidly evolving treatment landscapes in oncology. With over 80 active trials on ClinicalTrials.gov and 38 currently recruiting, the molecular complexity of AML — spanning FLT3, IDH1/2, NPM1, TP53, and dozens of other mutations — means that new targeted agents are entering clinical development at a pace that's difficult to follow manually.

Key signals to monitor in the AML landscape:

• Menin inhibitor trials (revumenib, ziftomenib, and competitors) — one of the hottest mechanisms in AML
• Venetoclax + novel combination regimens in newly diagnosed and relapsed/refractory settings
• Next-generation FLT3 inhibitors and dual FLT3/KIT/AXL inhibitors
• IDH1 and IDH2 inhibitor combinations and sequencing trials
• CD33, CD123, and CLL-1 targeted antibody-drug conjugates and bispecifics
• Hypomethylating agent backbone combinations in older/unfit patients

What we monitor for AML

Our pipeline pulls directly from the ClinicalTrials.gov API every morning. For an AML watch profile, configure:

• Condition keywords: "acute myeloid leukemia", "AML", "FLT3 mutant AML", "IDH1 AML", "secondary AML", "myelodysplastic syndrome AML"
• Phase filter: Phase 1 only (early pipeline), Phase 2/3 (late-stage), or all phases
• Sponsor filter: Industry-sponsored only (competitive intelligence) or all sponsors including NCI and academic centers
• Status filter: Recruiting only, or all active trials including those not yet recruiting

The AML treatment landscape in 2026

Menin inhibitors — the next class of targeted agents

The approval of revumenib (Revuforj) in NPM1-mutant and KMT2A-rearranged AML validated menin inhibition as a clinically actionable mechanism. Multiple competitors are now advancing their own menin inhibitors through Phase 1/2 trials, and combination regimens with azacitidine, venetoclax, and standard induction chemotherapy are actively enrolling. Monitoring trial registrations is the earliest signal of how this class will be expanded.

Venetoclax combinations beyond the standard of care

Venetoclax + azacitidine established a new standard for older/unfit patients and is now generating numerous spin-off trials: triple combinations with FLT3 inhibitors, IDH inhibitors, and novel targeted agents. Researchers and pharma teams tracking these combinations need systematic visibility into which backbone regimens are being tested and by whom.

Antibody-drug conjugates and bispecifics

The success of CD33-directed therapies has renewed interest in ADCs and bispecific T-cell engagers targeting AML antigens. CD33, CD123, CLL-1, and FLT3 are all active targets. Multiple bispecific programs from Pfizer, AbbVie, and mid-cap biotechs are advancing through early-phase trials in relapsed/refractory disease.

Transplant conditioning and post-transplant maintenance

Allogeneic stem cell transplant remains central to AML management. A wave of trials is examining novel conditioning regimens, graft-versus-host disease prevention, and post-transplant maintenance with targeted agents — an often-overlooked segment of the AML trial landscape.

Who uses AML trial monitoring

Hematology-oncology pharma teams

BD and competitive intelligence teams at companies with AML programs systematically track competitor trial registrations. A new IND filing or Phase 2 trial start can reveal competitor development strategy months before any public presentation.

Academic hematologists and trialists

Physician-scientists at academic medical centers monitor trial registrations to identify collaboration opportunities, understand overlapping trial designs, and ensure their own investigator-initiated studies are differentiating from commercial programs.

Biotech investors

AML is a high-value target indication. Investors monitoring early Phase 1 trial initiations gain earlier visibility into program value than those relying on press releases or conference presentations.

Frequently asked questions

How current is the AML trial data?

Our pipeline fetches from ClinicalTrials.gov every morning. Studies posted or updated in the preceding 24 hours appear in that day's digest.

Can I track specific AML subtypes separately?

Yes. On the Starter plan ($49/month), you can create up to 5 search profiles. For example: one profile for FLT3-mutant AML, another for IDH1/2-mutant trials, and a third for all Phase 3 recruiting trials regardless of molecular subtype.

Does this cover international AML trials?

ClinicalTrials.gov includes trials with international sites, so major industry-sponsored programs from European and Asian sponsors are captured — particularly those with US enrollment sites.

How is this different from ClinicalTrials.gov alerts?

ClinicalTrials.gov offers basic RSS alerts without phase filtering, sponsor type filtering, or clean digest formatting. DataLookout provides the intelligence layer: filtered, labeled, and organized alerts for AML specifically.